Dexcom (DXCM) Equity Average (2011 - 2026)

Dexcom (DXCM) has 16 years of Equity Average data on file, last reported at $2.9 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $2.9 billion, up 30.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 30.53% YoY), and the FY2025 annual result was $2.4 billion, up 16.24% from the prior year.
• Equity Average grew to $2.9 billion in Q1 2026 per DXCM's latest filing, from $2.7 billion in the prior quarter.
• Over five years, Equity Average peaked at $2.9 billion in Q1 2026 and troughed at $2.0 billion in Q4 2022.
• A 5-year average of $2.3 billion and a median of $2.2 billion in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2024 and 2025: Equity Average fell 5.88% in 2024, then jumped 34.07% in 2025.
• A 5-year view of Equity Average shows it stood at $2.0 billion in 2022, then gained by 9.61% to $2.2 billion in 2023, then slipped by 5.88% to $2.0 billion in 2024, then surged by 34.07% to $2.7 billion in 2025, then rose by 4.22% to $2.9 billion in 2026.
• Business Quant data shows DXCM's Equity Average at $2.9 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.6 billion in Q3 2025.